瑞加诺生诱发偏瘫型偏头痛一例
本文报告一例有偏瘫型偏头痛史的患者在接受瑞加诺生负荷PET心肌灌注显像时出现左侧无力和头痛,影像学排除脑血管意外,症状1小时内改善并于24小时内完全缓解,为首次报道瑞加诺生触发偏瘫型偏头痛。
要点
- 瑞加诺生负荷试验可能触发偏瘫型偏头痛,尤其有偏瘫型偏头痛史者。
- 症状出现后需影像学排除脑血管意外,本例影像正常且24小时内完全缓解。
- 有偏瘫型偏头痛史者应谨慎避免使用瑞加诺生和腺苷。
核心结论
- 瑞加诺生触发了该患者的偏瘫型偏头痛发作,此前文献未见报道。
- 有偏瘫型偏头痛史者避免使用瑞加诺生和腺苷可能是审慎的。
研究设计与样本
- 本文为单例病例报告,描述一例有偏瘫型偏头痛史患者接受瑞加诺生负荷PET心肌灌注显像后的不良反应。
主要发现
- 患者接受瑞加诺生后出现左侧无力和头痛,排除脑血管意外的影像学检查正常。
- 症状在发作1小时后显著改善,24小时内完全缓解。
临床怎么用
- 对拟行瑞加诺生负荷心肌灌注显像者应询问偏瘫型偏头痛史。
- 有偏瘫型偏头痛史者考虑避免使用瑞加诺生和腺苷。
局限性
- 本文为单例病例报告,无法确定因果关系或发生率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SPECT and PET myocardial perfusion imaging (MPI) are widely used to evaluate patients for coronary artery disease. Regadenoson (a selective A2A adenosine receptor agonist) is a commonly used vasodilator agent for stress MPI because of its safety profile and ease of use. Common adverse reactions such as headache, shortness of breath, flushing, and chest and abdominal discomfort are typically mild and can be effectively reversed using methylxanthines such as aminophylline and caffeine. Neurological adverse reactions such as seizure and stroke have rarely been reported with the use of regadenoson. The hemodynamic changes associated with regadenoson administration, such as an exaggerated hypotensive or hypertensive response, may be the cause for the reported cerebrovascular accidents. Activation of central nervous system A2A adenosine receptors is thought to be responsible for seizure episodes in patients with or without known histories of seizure. A2A adenosine receptors activation is also believed to play a role in headaches and migraine. This patient reported who has a history of hemiplegic migraine developed left side weakness and headache following the administration of regadenoson during a PET MPI study. Imaging work-up to rule out cerebrovascular accident was normal. After 1 hour from the onset of his symptoms, his weakness and headache significantly improved with complete resolution within 24 hours. We concluded that regadenoson triggered a hemiplegic migraine episode in this patient, which has not been previously reported in the literature. It may be prudent to avoid regadenoson and adenosine use in patients with a history of hemiplegic migraine.
引用
- Elsadany M, McMahon SR, Mehla S, et al. Hemiplegic migraine episode triggered by regadenoson. J Nucl Cardiol. 2021. PMID: 34308528. doi:10.1007/s12350-021-02736-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。